Telithromycin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Community Acquired Pneumonia (CAP)

Conditions

Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB)

Trial Timeline

May 1, 2004 → Dec 1, 2004

NCT ID

NCT00546676

About Telithromycin

Telithromycin is a approved stage product being developed by Sanofi for Community Acquired Pneumonia (CAP). The current trial status is completed. This product is registered under clinical trial identifier NCT00546676. Target conditions include Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB).

What happened to similar drugs?

1 of 12 similar drugs in Community Acquired Pneumonia (CAP) were approved

Approved (1) Terminated (2) Active (9)

✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved

🔄Ceftaroline + CeftriaxonePfizerPhase 3

🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3

🔄tigecyclinePfizerPhase 3

🔄Azithromycin SRPfizerPhase 3

❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00288223	Approved	Terminated	Jan 1, 2006	Jan 1, 2007	Bronchitis, Chronic
NCT00261105	Approved	Completed	Feb 1, 2005	Dec 1, 2005	Respiratory Tract Infections
NCT00174694	Approved	Completed	Nov 1, 2004	—	Sinusitis
NCT00546676	Approved	Completed	May 1, 2004	Dec 1, 2004	Community Acquired Pneumonia (CAP)
NCT00132938	Approved	Completed	Jan 1, 2004	May 1, 2006	Chronic Bronchitis
NCT00538018	Approved	Completed	Jan 1, 2003	Jun 1, 2004	Pneumonia
NCT00273520	Phase 3	Completed	Jan 1, 2003	May 1, 2004	Asthma
NCT00537563	Phase 3	Completed	Dec 1, 2002	Sep 1, 2003	Maxillary Sinusitis
NCT00538148	Approved	Completed	Nov 1, 2002	Sep 1, 2004	Bronchitis, Chronic

Competing Products

17 competing products in Community Acquired Pneumonia (CAP)

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	35
Ticagrelor + Placebo	AstraZeneca	Phase 2	27
Ceftaroline + Ceftriaxone	Pfizer	Phase 3	40
Azithromycin microspheres 2.0 single dose	Pfizer	Phase 3	40
tigecycline	Pfizer	Phase 3	40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin	Pfizer	Approved	43
Azithromycin SR	Pfizer	Phase 3	40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
Azithromycin SR + Amoxiclav	Pfizer	Pre-clinical	18
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
tigecycline	Pfizer	Phase 3	40
Zinforo (ceftaroline fosamil)	Pfizer	Pre-clinical	26
Tigecycline + Levofloxacin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Phase 3	40
Omadacycline + Moxifloxacin	Zai Lab	Phase 3	41
ceftobiprole medocaril + IV standard-of-care cephalosporin	Basilea Pharmaceutica	Phase 3	34
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days	Enanta Pharmaceuticals	Phase 2	21